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Abstract
Consumption of carbohydrate-containing foods leads to transient postprandial rises in blood glucose concentrations that vary between food
types. Higher postprandial glycaemic exposures have particularly been implicated in the development of chronic cardiometabolic diseases.
Reducing such diet-related exposures may be beneficial not only for diabetic patients but also for the general population. A variety of
markers have been used to track different aspects of glycaemic exposures, with most of the relevant knowledge derived from diabetic
patients. The assessment of glycaemic exposures among the non-diabetic population may require other, more sensitive markers. The
present report summarises key messages of presentations and related discussions from a workshop organised by Unilever intended to
consider currently applied markers of glycaemic exposure. The particular focus of the meeting was to identify the potential applicability
of glycaemic exposure markers for studying dietary effects in the non-diabetic population. Workshop participants concluded that markers
of glycaemic exposures are sparsely used in intervention studies among non-diabetic populations. Continuous glucose monitoring remains
the optimal approach to directly assess glycaemic exposure. Markers of glycaemic exposure such as glycated Hb, fructosamine, glycated
albumin, 1,5-anhydroglucitol and advanced glycation end products can be preferred dependent on the aspect of interest (period of
exposure and glucose variability). For all the markers of glycaemia, the responsiveness to interventions will probably be smaller among
the non-diabetic than among the diabetic population. Further validation and acceptance of existing glycaemic exposure markers applied
among the non-diabetic population would aid food innovation and better design of dietary interventions targeting glycaemic exposure.
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Introduction (Marjan Alssema)
Consumption of carbohydrate-containing foods leads to
varying levels of transient postprandial rises in blood glucose.
Higher levels of postprandial glycaemic exposures have
been implicated in the development of chronic cardiometabolic
diseases, particularly type 2 diabetes mellitus (T2DM) and
CVD(1). Patients with T2DM are particularly exposed to
higher blood glucose levels, due to both fasting glucose and
postprandial glucose excursions. Recent guidelines from the
International Diabetes Federation advise the active treatment
of postprandial glucose with pharmacological therapy as well
as dietary intervention in these patients(2). Although much
less evidence is available for the non-diabetic population,
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there is broad consensus that reducing the exposure to high
postprandial glucose concentrations is beneficial for their
health too(3).
Glycated Hb (HbA1c) is the most accepted marker to
evaluate the longer-term blood glucose control in diabetic
patients. However, there are hardly any data on the use of
HbA1c or other glycaemic exposure markers in (dietary)
intervention trials among non-diabetic individuals, i.e. those
with normal or impaired glucose tolerance (IGT) who experi-
ence lower and more sustained glycaemic exposure. Diets can
have an impact on postprandial glucose concentrations also in
the non-diabetic population; however, it is unclear whether
current markers are sensitive to (smaller dietary) changes in
glycaemic exposure. Such information would be particularly
relevant to evaluating the efficacy of dietary and lifestyle
approaches on glycaemic exposure in the general population
and its role in reducing disease risks.
To address this challenge, Unilever organised a workshop
with experts on diet and glycaemia on 16–17 December 2013,
in Vlaardingen, The Netherlands. The workshop was attended
by scientists from academia and Unilever. The present report
summarises the key messages of the presentations held and
related discussions among the wider audience. On the first
workshop day, we focused on the relevance of postprandial
glucose lowering and comprised presentations on the food
industry perspective, the physiological consequences of post-
prandial glucose lowering, and the underlying mechanisms
leading to postprandial glycaemic exposure. On the 2nd day,
we addressed how glycaemic exposure can be measured. The
presentations included the characteristics (glucose variability)
and use of different glycaemic exposure markers. Thereafter,
the knowns and unknowns of the applicability of glycaemic
exposure markers in the non-diabetic population were
discussed and summarised. The ultimate objectives of the
meeting were to review present knowledge and consensus
about the characteristics of currently applied markers of
glycaemic exposure and the applicability of such markers
among the non-diabetic population.
The food industry perspective on postprandial glucose
lowering (David Mela)
Most large global food manufacturers have stated goals for
monitoring and improving the nutritional quality of their
products and portfolio. For example, under the Unilever
Sustainable Living Plan, Unilever has set out a range of specific
nutrition targets for improving the health and well-being of
consumers(4). Given the increasing burden of T2DM world-
wide, there is a growing interest to see where manufactured
foods can make a contribution to reducing the prevalence
and risks of this disease. Unilever as well as other food
manufacturers are therefore looking at how dietary
approaches might help in reducing glycaemic exposures,
and in particular reduce postprandial glucose (and insulin)
responses.
Food industry approaches to the delivery of health benefits
differ in important ways from pharmaceutical approaches.
Most importantly, diet would always be seen as one
contributor to a healthier lifestyle and reduced disease risks,
but individual foods will never be claimed to treat, prevent
or cure disease. Individual foods can, however, have
beneficial physiological effects that may be linked to a poten-
tial for improving public health in the general population, and
can have a wide reach in terms of numbers of consumers and
consumption occasions. While individuals with diabetes and
IGT may not be the specific target group for such products,
these groups that in particular experience hyperglycaemia
have a significant and growing presence within the general
consumer population.
The reduction of glycaemia is generally endorsed by experts
as a health-relevant target for dietary intervention(2,3). This
view is also reflected in regulatory views on product health
claims. The European Food Safety Authority has stated that
the reduction of postprandial glycaemia may be a beneficial
physiological effect, provided postprandial insulin is not dis-
proportionally increased(3). Evidence for the effects of foods
on postprandial glucose and insulin concentrations is derived
from acute testing, typically involving single exposures and
monitoring of measures for 2–3 h postprandially. The
European Food Safety Authority furthermore cites the
‘maintenance’ of normal blood glucose concentrations as a
beneficial physiological effect. The required substantiation
for such an effect is an improvement in HbA1c over a
period of 12 weeks, while fasting and post-load glucose as
well as fructosamine are regarded as ‘supportive evidence’.
The scientific evidence underpinning the suggested health
relevance of postprandial glucose lowering is largely derived
from studies with gut-active enzyme inhibitors (e.g. acarbose,
miglitol)(5,6), the effects of postprandial glucose-lowering
diets(7,8) and observational data on lower-glycaemic index
(GI) or load diets(9,10).
The use of HbA1c as the accepted marker to evaluate blood
glucose exposure stems from its use in clinical practice to
monitor glycaemic control in diabetic patients. HbA1c is
recognised as a marker of future risk of diabetes compli-
cations, and many intervention and epidemiological studies
have supported its relationship to micro- and macrovascular
complications(11). Furthermore, since HbA1c is accepted as a
diagnostic criterion for diabetes, it is also a direct measure
of diabetes risk. However, accepted markers of disease risk
(such as HbA1c) may not necessarily be the most appropriate
for assessing glycaemic exposure for a given research setting,
depending on the objectives, population of interest, timings,
costs, etc. (Fig. 1). HbA1c is a marker reflecting long-term
glycaemic control (3 months), not shorter-term responses
(weeks, days or hours). Unfortunately, at present, there is limi-
ted endorsement for any specific markers of (diet-induced)
glycaemic exposures between acute (postprandial glucose)
and 3 months (HbA1c). In addition, among non-diabetic
populations, there is relatively little information on the use
of HbA1c and other glycaemic exposure markers. Academic
and industrial research and food innovation will benefit
from expert-endorsed markers appropriate for the general
population, which can be used for evaluating, substantiating
and communicating product benefits.
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The role of postprandial glucose and insulin in
the pathophysiology and onset of diabetes
(Andreas F. H. Pfeiffer)
It is established that increased postprandial glucose precedes
the development of type 2 diabetes as identified by the oral
glucose tolerance test as a diagnostic criterion of IGT. However,
there is no strong evidence for a pathophysiological role of
postprandial glucose in the development of T2DM in the
absence of insulin resistance or b-cell dysfunction in a healthy
organism. High-GI diets increased insulin resistance as
measured by homeostasis model assessment values in the
DIOGenes study(12), but showed variable associations with
the risk of diabetes(9). In particular, in observational studies
where the assessment of GI/glycaemic load is done by a FFQ,
and where (residual) confounding of, for example, fibres
may play a role, the interpretation of such findings remains
challenging. Moreover, the GI was variably associated with
intima–media thickness as a predictive marker of athero-
sclerosis and cardiovascular events in controlled studies(13).
There is evidence that acarbose reduces the incidence of
T2DM in patients with IGT(5); however, it is unclear whether
this should be seen as prevention, delay or masking of diabetes.
In established T2DM, elevated glucose concentration is
clearly related to the development of micro- and macro-
vascular complications. However, it is unresolved whether
the risk of complications is more related to postprandial
glucose and the amplitude of glucose excursions or to average
glucose as measured by HbA1c. While numerous biomarkers
are clearly increased depending on postprandial glucose
excursions, their relationship to disease risk is debated.
Regarding macrovascular complications, studies supporting
both views have been presented, such as the Nateglinide
and Valsartan in Impaired Glucose Tolerance Outcomes
Research study(14) and the Diabetes Intervention Study from
Dresden(15). A Cochrane systematic review and meta-analysis
of a-glucosidase inhibitors in type 2 diabetic patients has
shown that a-glucosidase inhibitors have a clear beneficial
effect on glycaemic control and post-load insulin levels but
not on plasma lipids(6). A positive effect of lowering post-
prandial glucose by acarbose has also been shown on atrial
natriuretic peptide, a biomarker indicating beneficial effects
on the heart(16). As a natriuretic peptide, this is one of the
vascular protective agents, and this hormone is known to
decrease during an oral glucose tolerance test. Since HbA1c
depends on both average fasting and postprandial glucose
concentrations, both components are likely to contribute.
Postprandial glucose metabolism plays an important role in
hepatic fat accumulation(17) and inflammatory responses(18,19).
A group that is likely to profit significantly from good control
of postprandial glucose and nutritional interventions are
obese people with the metabolic syndrome and large excursions
of insulin and postprandial glucose after meals. Among indivi-
duals with IGT, nutrition therapy clearly provides powerful
tools to prevent progression to diabetes, as has been shown
in the Diabetes Prevention Study and Diabetes Prevention
Program(20,21). Moreover, dietary interventions using high total
fat based on low-carbohydrate, high-MUFA and PUFA strategies
(Mediterranean diet) have been shown to reduce cardiovascular
events without weight loss or exercise(22). A third approach
consists of the use of increased protein contents, which improves
postprandial glucose by accelerating and augmenting fast
insulin secretion while reducing overall insulin requirements(23).
This may also be achieved by high-protein snacks preceding
meals(24). Protein from plant sources appears to differ from
animal protein, particularly red or processed meat(25). Diets
high in animal protein are associated with an increased risk of
diabetes, which is not the case for diets high in plant protein(25).
Since many people avoid plant protein due to associated soluble
fibres in legumes and intestinal discomfort, there is much
potential for the development of healthy foods based on plant
protein. Further components of great interest are dietary fibres
and whole grains. Primarily non-soluble cereal fibres have been
associated with a decreased risk of diabetes(26) and CVD(27).
Findings from prospective cohort studies showed that whole
grain intake is inversely associated with the risk of T2DM, and
this association is stronger for bran than for germ(26). A hypothesis
could be that cereal fibre intake is associated with higher insulin
sensitivity, which has been confirmed in the Framingham
Offspring Study(28) and in a recent human intervention trial(29).
These foods would be attractive for people aiming at a healthy
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Fig. 1. Markers of glycaemic exposure and markers of disease risk are the estimates of different reference points. The same marker can be a reflection of both
exposure and disease risk. Postprandial glucose and 1,5-anhydroglucitol (1,5-AG) are examples of the markers of recent glycaemic exposure. Glycated Hb
(HbA1c) and advanced glycation end products (AGE) in tissues are the markers of chronic, but not recent, exposure and are also the accepted markers of disease
risk. A colour version of this figure can be found online at journals.cambridge.org/bjn
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In conclusion, the evidence for a health benefit of reducing
glycaemic exposure is so far not conclusive, in particular for
the general ‘healthy’ population. Studies with GI-lowering
diets provide some evidence, but the interrelationship with
fibres and resistant starch makes them difficult to interpret.
Large intervention trials with acarbose in (pre)diabetes do pro-
vide the strongest evidence. Studies on the biomarkers of
heart, liver function and inflammation have suggested that the
metabolic effects of postprandial glucose-lowering interven-
tions may be physiologically broad and require further study.
Metabolic routes underlying postprandial glycaemia
(Hanny M. Boers and Marion G. Priebe)
Postprandial glycaemia is not only determined by glucose
influx from food (exogenous glucose), but also by glucose
production by the liver (endogenous glucose) and glucose
uptake in tissues (disposal). For reliable estimation of the
different factors that determine the postprandial glucose
response (influx, production and disposal), the dual-label
isotope technique can be used by labelling the starch in the
food products with 13C (influx) and infusing the volunteers
with a tracer amount of D-[6,6-2H2]glucose (disposal)
(30–32).
As shown by isotope labelling studies, starch consumption
can have an impact on the glycaemic response by affecting
glucose influx(33), glucose disposal(33,34) or endogenous
glucose production(35), or by a combination of these(33).
Therefore, the overall blood glucose response is not the
same as starch digestibility, the latter varying widely between
foods (even within one food group). Starch digestibility can be
predicted by an in vitro assay(36) and is often assumed to be
the basis for variation in GI. However, this is inherently
wrong, because the GI is determined not only by starch
digestibility but also by glucose production and disposal.
Recent studies have shown that glycaemic responses are
achieved by fluctuations in more than one factor. Priebe
et al.(35) showed that a lower glycaemic and insulin response
of wheat bread during the first 2 h compared with glucose in
water was not due to a lower glucose influx from bread, but
to a lower endogenous glucose production in the liver.
Eelderink et al.(37) showed that glycaemic response was the
same for bread and pasta, but influx of glucose was lower
for pasta than for bread (30 %) as was glucose disposal(33).
In conclusion, the different metabolic routes by which foods
can have an impact on the overall blood glucose response
must be taken into account for a mechanistic understanding
of food impacts on glycaemia.
Markers of glucose variability and postprandial peaks
(Antonio Ceriello)
There are indications that glycaemic variability, beyond HbA1c,
has an impact on the development of diabetes compli-
cations(38,39). The overall glycaemic exposure as reflected by
HbA1c does not necessarily reflect the glycaemic variability that
an individual is exposed to. For example, from continuous
glucose monitoring (CGM) studies in type 1 diabetes, it is
known that even patients in good glycaemic control can experi-
ence wide glucose fluctuations(40). Glycaemic variability over
the day (in contrast to between days) is importantly determined
by meal intake and physical exercise. Oxidative stress is the
putative link between glycaemic variability and endothelial
dysfunction, ultimately leading to diabetic complications(39).
Although the precise mechanism is not completely resolved,
thereare indications fromclinical studies that ahighdegreeofgly-
caemic variability (glucose oscillations), more than chronic
hyperglycaemia, leads to oxidative stress and endothelial dys-
function(41,42). These effects have been shown during spon-
taneous glucose oscillations in T2DM patients as well as during
inducedglucoseoscillations inbothnormal glucose-tolerant indi-
viduals and diabetic patients(41,42).
Although a certain degree of variability has also been
observed in subjects with normal glucose tolerance, glucose
variability increases in individuals with diabetes and in those
with impaired blood glucose regulation (impaired fasting
glucose and IGT). Therefore, it becomes crucial not merely
to identify the boundary beyond which glucose variability
takes on a pathological meaning, but, more importantly, to
better define the concept of glucose variability. A clear
consensus on the gold-standard method to measure glucose
variability in clinical practice and research is still lacking,
although a number of indicators have been proposed(43).
Some of the most frequently used methods are reviewed
below. Many of the current marketed CGM devices provide
more than one of these estimates of glycaemic variability,
and normative values have now been described(44).
Postprandial glucose, mean blood glucose and standard
deviation
Relatively straightforward measures of glucose variability
include the direct measurement of postprandial glycaemia,
the mean blood glucose level and its standard deviation.
Postprandial hyperglycaemia can be measured simply by
monitoring postprandial glycaemia 1–2 h after meals.
Standard deviation, an index of the dispersion of data around
mean blood glucose, was initially viewed as the simplest
approach for the evaluation of glucose variability, beyond the
determination of mean blood glucose. It has very recently been
observed that it is only in type 1 diabetes mellitus that there is a
linear relationship between HbA1c (an expression of the mean
plasma concentration of glucose) and glucose variability, and
this is particularly the case in subjects with higher HbA1c
levels(45). The authors concluded that these findings indicate
that reducing glycaemic variability in patients with poor glycae-
mic control can help improve HbA1c.
J index and CV
The imperfect relationship between mean blood glucose and
standard deviation can be partly resolved using indices that
correct the standard deviation for mean blood glucose, such as
the CV, i.e. the relationship between standard deviation and
the absolute value of the arithmetic mean glycaemia or the
J index(46). One of the limits and therefore one of the
criticisms of the use of standard deviation and related indices
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is that standard deviation considers all the excursions without,
however, giving a different weight to major and minor swings.
Mean amplitude of glucose excursion
The mean amplitude of glucose excursion is the meanof the daily
glucose excursions that exceed the standard deviation measured
over the 24h period. It is based on the use of continuous blood
glucose monitoring over 24h or, albeit with certain reserves, on
complete seven-point blood glucose profiles to calculate the
mean and standard deviation, and considers only major glucose
excursions(47). The mean amplitude of glucose excursion is
probably one of the most applied indices of glucose variability.
Continuous overlapping net glycaemic action
The recently introduced continuous overlapping net glycaemic
action (CONGA) index is an indicator of within-day glucose
variability(48). After the first number of hours of observation,
obtained by means of CGM, it calculates the difference between
current observation and observation in the previous hours.
CONGA is defined as the standard deviation of the recorded
differences. The higher the CONGA value, the greater the
glycaemic excursion. The frequently used parameters,
CONGA1, CONGA2 and CONGA4, coincide with observations
lasting 1, 2 or 4 h, and they are, therefore, expressions of glucose
variability within these intervals.
Low blood glucose index, high blood glucose index,
average daily risk range and blood glucose risk index
These parameters were developed by Kovatchev starting from
1998, as a logarithmic transformation of self-monitoring of
blood glucose data(49,50). The logarithmic transformation is
required to give a normal distribution to the otherwise asym-
metric glycaemic scale. Indeed, the hyperglycaemic range
between 10 and 33 mmol/l (180 and 600 mg/dl) is far greater
than the hypoglycaemic range below 4·4 mmol/l (80 mg/dl),
and the normal range between 4·4 and 10 mmol/l (80 and
180 mg/dl) is not exactly ‘central’ to the entire possible
glycaemic scale. The low blood glucose index (LBGI) and
high blood glucose index (HBGI) represent the frequency and
extent of low and high blood glucose measurements, respect-
ively. Higher LBGI and HBGI values indicate more frequent or
more extreme hypo- and hyperglycaemia, respectively. The
LBGI and HBGI can be obtained from both self-monitoring of
blood glucose and CGM data and can therefore be used to
calculate the blood glucose risk index, LBGI þ HBGI, an
indicator of the risk of experiencing extreme glycaemic values.
The average daily risk range is calculated using 2–4 weeks of
self-monitoring data, but requires a glycaemic monitoring
frequency of at least three measurements per day(51).
In conclusion, many indices of glycaemic variability have
been developed, validated and demonstrated to be useful
indicators of glycaemia. However, there is no consensus
about what could be the standard measure of glycaemic vari-
ability for diabetic patients, in part because most measures of
glycaemic variability indicate different aspects of glycaemia.
Current data on glucose variability among non-diabetics are
too scarce to evaluate the best marker in this population
that experiences less glycaemic variability.
Alternative markers of glycaemia and their use in the
general population (Eric S. Kilpatrick)
CGM or multiple within-day measures of pre- and postpran-
dial glucose are the ideal way of assessing glycaemia in both
diabetic and non-diabetic populations. However, these
measures are laborious, time-consuming and costly, so
alternative markers of glycaemia are routinely used in
managing patients with diabetes, and these markers can be
considered for use in subjects without diabetes(52). An
important difference among these glycaemic markers is the
time frame of previous glycaemic exposure that is reflected
(Fig. 2); however, other characteristics of such markers also
define their applicability and use.
HbA1c is well established among clinicians as a tool to
monitor glucose control, and there is strong evidence of HbA1c
beingamarkerof complications(53).HbA1cmeasures theglycation
of Hb and gives an indication of glycaemia over the previous
6–8 weeks, with recent glycaemia having a greater influence on
the result than glycaemia in the past(54). Between individuals, the
same HbA1c value canbe associatedwith a range ofmeanglucose
values. For example, within the non-diabetic range, some subjects
withanHbA1cof31mmol/mol (5%)will havea truemeanglucose
of 4·2mmol/l, while others will have a mean of 6·7mmol/l(55).
However,within the samepatient,HbA1c iswell placed at tracking
changes in their glycaemic control over time. The contribution of
postprandial hyperglycaemia to the HbA1c value is still debated,
but it would appear that it is unlikely to contribute more to the
concentration than would be expected(56).
Serum fructosamine is a relatively non-specific marker of
serum protein glycation. It gives an indication of glycaemia
over a shorter period of time compared with HbA1c (1–3
weeks), which can be an advantage in some clinical situations,
such as pregnancy, and where HbA1c may give unreliable
results. Glycated albumin assays generally provide a more
specific assessment of protein glycation over the same
period of time as fructosamine(57). In some studies, glycated
albumin concentrations have been found to reflect postpran-
dial hyperglycaemia better than pre-prandial, although the
Fructosamine/
glycated albumin






Fig. 2. Markers of glycaemic control and their temporary reflection of glycae-
mic exposure. 1,5-AG, 1,5-anhydroglucitol; HbA1c, glycated Hb.
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mechanism for this remains unclear(58). In clinical practice,
both fructosamine and glycated albumin are regarded as
good alternatives for HbA1c measurement as these markers
are unaffected by haemoglobinopathies and anaemia.
Limitations for its clinical use are, however, that the treatment
targets are not clearly defined and that other factors such as
total protein concentrations (fructosamine only) and obesity
may have an impact on these levels as well. Glycated albumin
and fructosamine may also be the indicators of disease risk as
both have been associated with long-term microvascular
complications and incidence of diabetes(59,60).
An indicator of postprandial glycaemia that would appear to
be particularly valuable is 1,5-anhydroglucitol (1,5-AG)(61), as
rises in blood glucose concentrations will lead to glycosuria,
which, in turn, increases the urinary loss of 1,5-AG and therefore
a fall in serum values. The renal threshold is therefore an
important determinant of 1,5-AG,which may limit interpretation
in circumstances that affect the threshold (such as pregnancy).
The correlation with HbA1c and glucose is rather low(62),
potentially reflecting the fact that these measures reflect
different aspects of glycaemia. Within the non-diabetic range,
glycaemia will probably seldom exceed the patients’ renal
thresholds for glucose and so 1,5-AG is unlikely to be a useful
marker in this group of subjects. The relevance of markers in
particular reflecting postprandial hyperglycaemia, among
others, lies in the notion that postprandial, more than fasting,
glucose levels are generally regarded as a strong risk factor for
cardiovascular complications. Although there are currently
only a few intervention trials that have studied the cardiovascu-
lar effects of lowering postprandial glucose as such(63–65), these
trials have also shown that in diabetic patients, it is difficult to
achieve the target for postprandial glucose lowering(64,65).
Nevertheless, many large-scale epidemiological studies have
confirmed the prospective association of post-load or postpran-
dial glucose with CVD(66,67). So far, few data are available on the
relationship of 1,5-AG with disease. In the Atherosclerosis Risk
in Communities (ARIC) study, 1,5-AG has been shown to be
associated with incident diabetes independent of HbA1c and
glucose(68). More prospective studies on end points are clearly
needed to validate the use of 1,5-AG as a marker of disease risk.
CGM is still the optimal approach to fully assess glucose
excursions in the diabetic as well as in the non-diabetic popu-
lation. A new technique measuring glucose in the interstitial
fluid is less invasive and provides good estimates of postprandial
glucose(69). Importantly, it has been proven to be highly accep-
table to users and may thus provide a good alternative to
established devices(69). This approach may be an attractive way
forward for evaluating food effects on glycaemic exposure.
In conclusion, although CGM remains the optimal approach
to assess glycaemic exposure, routine and less laborious
markers have also been extensively used. HbA1c is the best-
established marker of glycaemic control in clinical practice.
Markers other than HbA1c can be appropriate for use when
a measure of shorter duration of glycaemia or glucose vari-
ability is sought or when HbA1c is known to be unreliable
(e.g. in individuals with haemoglobinopathy, anaemia or
end-stage renal disease). The less-invasive novel approach
of measuring interstitial glucose may provide an interesting
way forward in evaluating glycaemic exposure among
individuals with or without diabetes.
Glycated Hb and advanced glycation end products as
markers of glycaemia (Bruce H. R. Wolffenbuttel)
Next to HbA1c, advanced glycation end products (AGE) are
long-term markers of glucose control either in the form of
Hb-AGE in erythrocytes(70) or accumulated in tissues(71). In
particular, HbA1c but also accumulated AGE have been well
validated as the predictors of CVD and other diabetic-related
complications(72–75). Much less is known about the determi-
nants of these markers, which is the topic of the brief
review presented below.
HbA1c is a standard measure of glycaemic exposure in clinical
practice and has been accepted as a diagnostic criterion for
diabetes. A substantial proportion of HbA1c is, however, deter-
mined by non-glycaemic factors. In the Lifelines Cohort Study,
it has been found in non-diabetic individuals that fasting plasma
glucose explains 11% of the inter-individual variation in HbA1c,
with other important contributing factors being non-glycaemic,
and the total model explains 26% of the variance(76). Deter-
minants have been demonstrated to be heritable for a large
part(77), with the heritable part being only to a minor degree
glucose-related. Indeed, genome-wide association studies
identified ten genetic loci associated with HbA1c. Of these,
seven map to loci where common variants probably influence
HbA1c levels via erythrocyte biology(78). The heritable factor
determining HbA1c also became evident from a study comparing
HbA1c levels across ethnically diverse groups. It has been found
that the level of HbA1c is, in general, approximately 0·3–0·5%
higher in Hispanics and at lower glycaemic levels also in Africans
and Asians when compared with Caucasians(79).
Tissue AGE accumulation can easily be measured non-
invasively by skin autofluorescence, and has also been
applied for screening of diabetes(71). In diabetic patients,
AGE accumulation in the skin has been associated with the
duration and severity of hyperglycaemia. Skin autofluore-
scence measures have been found to be related to age
(years), the duration of diabetes, creatinine levels and mean
HbA1c over the previous year, but not to the most recent
HbA1c measurement(71). AGE formed during heating of food
can also be partly absorbed and measured in serum, but
their contribution to AGE accumulation in tissues and its con-
sequences for health are currently unresolved(80). AGE in skin
collagen are assumed to provide a longer-term index of tissue
damage than HbA1c(71). Indeed, Hb-AGE in erythrocytes has
been demonstrated to respond more slowly to intensive treat-
ment than does HbA1c(70). AGE in skin collagen measured
by autofluorescence are regarded as an even more ‘static’
measurement, and it is currently unknown whether this
measure can be used for the evaluation of interventions.
In conclusion, both HbA1c and AGE are strong markers of
long-term disease risk, but it is evident from human genome-
wide association studies, studies in twins and population studies
that a substantial proportion of the variation in HbA1c and AGE
between individuals is determined by other (non-glycaemic)
factors. Where HbA1c reflects glycaemia over approximately
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5–6 weeks, AGE accumulation in the skin reflects glycaemia
over years. Whether AGE measured by autofluorescence can
be used to evaluate the differences within individuals and
the effect of ‘interventions’ still needs to be demonstrated.
Summary of discussion
Hyperglycaemic exposures in normoglycaemic individuals
are limited
It was generally recognised that so far, there is need for more
studies because only a few studies have reported continuously
measured glucose profiles in non-diabetic individuals over one
or more days. Most studies that have averaged group(81) or
individual(82) values over a number of days have shown that the
averaged glucose levels generally rise no higher than 7·8mmol/l
in response to meals(2). However, it may be expected that individ-
ual differences reflecting acute dietary effects are apparent from
real-time measures such as CGM. The few recent studies reported
on individual hyperglycaemic episodes have indeed indicated
that most normoglycaemic individuals do experience certain
episodes of hyperglycaemia that exceed the IGT or even the
diabetic threshold(82–84). Thus, although (postprandial) glucose
levels in normoglycaemic individuals are for the large majority
of the day indeed normoglycaemic, they seem to experience
occasional periods of hyperglycaemia in real-life conditions.
Reductions in glycaemic exposure in the non-diabetic
population (e.g. in response to dietary interventions) will
not be reflected in every marker that reflects glycaemic
exposure
It was assumed that even if certain periods of acute hyper-
glycaemia do exist in normoglycaemic individuals, variation
(e.g. as a result of different diets) in the markers of (sustained)
glycaemic exposure would be very small or not apparent in
this population. Since ‘normoglycaemic’ implies a well-
functioning level of control over both postprandial and fasting
glucose, the strongest change in glycaemic markers would be
expected when glucose tolerance is lower, or perhaps with
interventions that produce large and frequent differences in
postprandial glucose. Other factors that will determine the
effect size include the type of intervention, assay variability
and the nature of the marker (being dynamic or static). It may
be expected that 24 h glucose monitoring and glucose levels in
the oral glucose tolerance test will be more likely to reflect
reductions in glycaemic exposure as these markers are more
dynamic than others (e.g. HbA1c). Some markers are not
suitable to track changes in glycaemic exposure in the normo-
glycaemic population; for example, 1,5-AG would only reflect
glucose levels that result in glycosuria (9–10 mmol/l), which is
unlikely in the non-diabetic population.
Glycaemic exposure may be a risk factor for progression to
disease in an as-yet uncompromised population
The evidence of glycaemic exposure being a risk factor for
progression to disease in a healthy population has significant
support, but is not conclusive. The strongest evidence comes
from studies with acarbose in individuals at risk (IGT)(5), while
studies on low-GI diets are supportive(9,10). Nevertheless, as
noted, regulatory agencies generally view reduced glycaemic
impact of foods as a beneficial physiological effect.
Appropriate markers of glycaemic exposure are not
necessarily appropriate markers of disease risk
There is an important difference between a marker of exposure
(reflecting what has already happened) and a marker of risk
(predictor of what will happen). Additional data are required
to validate the markers of glycaemia as markers of disease risk.
HbA1c, fasting glucose and 2 h post-load glucose are widely
accepted as the markers of disease risk. More recently, fructo-
samine, glycated albumin and 1,5-AG have been validated in a
few studies as the markers of exposure that may also be markers
of disease risk; however, more data are needed to be able to
compare different markers.
Glycated Hb may not be the most appropriate glycaemic
exposure marker for validating the efficacy of (dietary)
glucose-lowering interventions in the non-diabetic
population
HbA1c is certainly most accepted as a glucose exposure
marker and (along with fasting blood glucose) benefits from
the existence of widely accepted ‘reference’ values. Reference
values are less well established for alternative markers,
making the clinical relevance of changes in other markers
harder to interpret. However, value of HbA1c only reflects glu-
cose levels over a longer time frame and its sensitivity will be
limited to individuals with IGT and diabetes.
Conclusions
The workshop participants agreed that reducing glycaemic
exposure is generally regarded as a physiological benefit,
and striving to develop dietary interventions and foods that
do so is potentially relevant for public health. However, the
evidence for a health benefit is so far not conclusive, in
particular for the general ‘healthy’ population. Studies with
low-GI diets, for example, provide some supportive evidence,
but the confounding effects of diet composition make the
results difficult to interpret purely in terms of glycaemic
exposures. Large intervention trials with acarbose in
(pre)diabetes provide the strongest evidence. Studies on bio-
markers of heart and liver function suggest that the beneficial
metabolic effects of postprandial glucose-lowering interven-
tions may be broad, and these effects could provide relevant
mechanistic support for a causal relationship between glycae-
mic exposure and disease risk. Furthermore, diet-related
reductions in postprandial glucose can be achieved via
impacts on processes other than just the rate of glucose
uptake, which is important for mechanistic understanding.
Overall, workshop participants agreed that markers of gly-
caemic exposures are sparsely used in intervention studies
among non-diabetic populations, and that most data on such
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markers are derived from diabetic patients. CGM remains the
optimal approach to directly assess glycaemic exposure, also
in the non-diabetic population. Continuous measurement of
‘interstitial’ glucose has the potential of being an acceptable
and less-invasive method in determining changes in glycaemic
exposure. Measurement of glycaemic variability also requires
CGM. Glycaemic variability can occur independent of overall
glycaemic exposure and is a complex concept; different
aspects of variability may require different measures. There
is no clear consensus about the optimal measures of glycaemic
variability among diabetic patients, let alone in non-diabetics.
Routine and less laborious markers of overall glycaemic
exposure provide attractive and feasible alternatives to CGM.
HbA1c remains the best-established marker that reflects
longer-term glycaemic exposure and disease risk in diabetic
patients. Alternative markers of glycaemic exposure such as
fructosamine, glycated albumin, 1,5-AG and AGE reflect differ-
ent aspects of glycaemic exposure and can be valuable depen-
dent on the aspect of interest (period reflected and glucose
variability). Generally speaking, it appears that markers
reflecting longer-term glycaemia such as HbA1c and AGE
have the best-established predictive relationship with future
chronic cardiometabolic disease risk. For all markers of
glycaemia, the responsiveness to intervention will probably
be smaller among non-diabetic than among diabetic popu-
lations. Further validation and acceptance of glycaemic
exposure markers for the general population would aid food
innovation and better design of dietary interventions targeting
glycaemic exposure.
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